Pomerantz LLP is investigating Johnson & Johnson for potential securities fraud following the company's Q3 2026 report showing net earnings of $210 million, heavily impacted by multi-billion dollar charges related to talc litigation settlements. The company also reported slower revenue growth of 2.5% in its MedTech segment due to pricing pressures in China and geopolitical issues in the Middle East. After the earnings announcement, J&J's stock dropped 5.73%. The investigation focuses on whether J&J and its executives engaged in unlawful business practices affecting investors.
As of Nov 04, 2026 06:02 WIB, Johnson & Johnson (JNJ) trades at USD 265.66 on Pluang, down 1.81% for the day. The stock shows a market cap of $651.32 billion and a dividend yield of 1.98%. Pluang investors currently lean more towards buying, with 62% of order activity in favor of purchases.
Retirees seeking steady income without selling shares can invest in three dividend stocks: Johnson & Johnson, Enterprise Products Partners, and Verizon. A $100,000 portfolio split evenly among these stocks yields about $4,700 annually, combining safe...
Four blue-chip companies—Procter & Gamble, Johnson & Johnson, PepsiCo, and Walmart—consistently raised their dividends through the 2008 financial crisis and the 2020 pandemic. These firms operate in essential sectors like groceries, healthcare, and s...
